NASDAQ: CADL - Candel Therapeutics, Inc.

Rentabilität für sechs Monate: -14.21%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Candel Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

weitere details
It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-07-27
ISIN US1374041093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.candeltx.com
Цена ао 7.5
Preisänderung pro Tag: -14.46% (6.95)
Preisänderung pro Woche: -26.24% (8.06)
Preisänderung pro Monat: -29.77% (8.465)
Preisänderung über 3 Monate: -32.98% (8.87)
Preisänderung über sechs Monate: -14.21% (6.93)
Preisänderung pro Jahr: +276.27% (1.58)
Preisänderung über 3 Jahre: +25.16% (4.75)
Preisänderung seit Jahresbeginn: -25.22% (7.95)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1064.07 1
P/BV 2.59 6
P/E 0 0
EV/EBITDA -0.5468 0
Gesamt: 3.5

Effizienz

Name Bedeutung Grad
ROA, % -90.98 0
ROE, % -297.68 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.5859 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -75.2 0
Rentabilität Ebitda, % 392.51 10
Rentabilität EPS, % 205.63 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Northpond Ventures, Llc 1935215 6.59
Sands Capital Ventures, LLC 811737 2.77
Vanguard Group Inc 425749 1.45
FMR, LLC 298384 1.02
Geode Capital Management, LLC 139253 0.47
Bridgeway Capital Management, Inc. 132595 0.45
Baystate Wealth Management LLC 76910 0.26
Blackrock Inc. 49285 0.17
OneDigital Investment Advisors LLC 29783 0.1
State Street Corporation 27600 0.09

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Micro-Cap ETF 0.03787 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01119 38.04 0.6026
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares UltraPro Russell2000 0.00323 89.82 1.47873
ProShares Hedge Replication ETF 0.00093 5.92 1.47892
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 ETF 0 17.16 1.48801
0.0131.851.23



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (57 Jahre)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (47 Jahre)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (64 Jahr)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (56 Jahre)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (40 Jahre)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (64 Jahr)

Adresse: United States, Needham. MA, 117 Kendrick Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.candeltx.com